Mynvax Gets A ‘Warm’ Welcome With A $4.2M Investment


Mynvax is a pre-clinical stage vaccine biotechnology startup that received $4.2 million in Series A funding round. This funding round was led by Accel Partners, LetsVenture and Kotak Investment Advisors. Other early stage angel investors that had previously provided backing during pre-series A also participated. Dr. Raghavan Varadarajan, Professor at the Indian Institute of Science, Bangalore and Dr. Nadig, an alumnus of the Institute founded Mynvax in 2017. The Society of Innovation and Development (SID), IISc incubated Mynvax. It aimed towards the advancement of innovative and broadly protective influenza vaccine technologies.

The vaccine can be stored at 37°C for over a month and at 100°C for up to 90 minutes. During this period, it does not lose its ability to fight the virus. Most...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments